Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.70
-0.05 (-0.74%)
Dec 11, 2025, 2:10 PM EST - Market open
Vanda Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Vanda Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14, which forecasts a 108.96% increase in the stock price over the next year. The lowest target is $11 and the highest is $20.
Price Target: $14 (+108.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vanda Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +198.51% | Nov 19, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +64.18% | Nov 5, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $13 → $11 | Buy | Maintains | $13 → $11 | +64.18% | Oct 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +198.51% | Aug 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $13 | Buy | Initiates | $13 | +94.03% | May 14, 2025 |
Financial Forecast
Revenue This Year
222.64M
from 198.77M
Increased by 12.01%
Revenue Next Year
270.66M
from 222.64M
Increased by 21.57%
EPS This Year
-2.35
from -0.33
EPS Next Year
-1.57
from -2.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 232.5M | 304.5M | |
| Avg | 222.6M | 270.7M | |
| Low | 211.5M | 231.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 17.0% | 36.8% | |
| Avg | 12.0% | 21.6% | |
| Low | 6.4% | 4.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.86 | -0.49 | |
| Avg | -2.35 | -1.57 | |
| Low | -3.44 | -2.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.